Paper Details

  1. Home
  2. Paper Details

[Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome].

Author: BelousovIu B, DemidovaM A, LeonovaM V, TarasovA V

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Moexipril, an angiotensin-converting enzyme inhibitor, effectively lowered blood pressure and improved vasodilating function in postmenopausal women with metabolic syndrome and hypertension. It also reduced total cholesterol, LDL cholesterol, and triglycerides in patients with obesity.
Paper Details　
Original Abstract of the Article :
Hypotensive, organoprotective, and metabolic effects of angiotensin converting enzyme inhibitor moexipril (7.5-15 mg/day for 16 weeks) with or without combination with hydrochlorothiazide was studied in 34 women (mean age 59.6+/-1.6 years) with postmenopausal metabolic syndrome and hypertension. Thi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/16858353

データ提供：米国国立医学図書館（NLM）

Hypotensive, Organoprotective, and Metabolic Effects of Angiotensin Converting Enzyme Inhibitor Moexipril in Women with Postmenopausal Syndrome

Postmenopausal women often experience a range of health challenges, including cardiovascular disease and metabolic disorders. This study investigates the effects of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, in women with postmenopausal syndrome. The researchers aimed to assess moexipril's impact on blood pressure, organ protection, and metabolic parameters in this population.

A New Oasis in the Desert of Postmenopausal Health

The study found that moexipril effectively lowered blood pressure in postmenopausal women with metabolic syndrome and hypertension. Moreover, it demonstrated a protective effect on the kidneys and improved vascular function. The study also revealed positive effects on lipid profiles, suggesting potential benefits for cardiovascular health.

Finding the Right Path Through the Desert

This research provides valuable information for clinicians managing postmenopausal women with cardiovascular and metabolic health challenges. The study's findings suggest that moexipril can be an effective treatment option for this population, offering potential benefits for blood pressure control, organ protection, and metabolic health.

Dr.Camel's Conclusion

This research explores the therapeutic potential of moexipril in postmenopausal women with metabolic syndrome and hypertension. The study's findings highlight the positive effects of moexipril on blood pressure, organ protection, and metabolic parameters, offering a promising treatment option for this population. It's like discovering a new oasis in the desert of postmenopausal health, offering a path towards improved cardiovascular health and overall well-being.

Date :
  1. Date Completed 2006-08-18
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

16858353

DOI: Digital Object Identifier

16858353

Related Literature

Article Analysis
・Effects of moexipril
SNS
PICO Info
in preparation
Languages

Russian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.